Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

MT-7117 Formulation Code C

MT-7117 Formulation Code C, MT-7117 Placebo

MaaT013

MomeGalen 1 mg/g cutaneous emulsion, Placebo to 0.1% mometasone furoate cutaneous emulsion (active ingredient-free vehicle of mometasone cutaneous emulsion), ECURAL Fettcreme, 1 mg/g Creme

Monofer, injektions- og infusionsvæske, opløsning

NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral

OCA 5MG IR +BZF 400 MG SR

OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

OPDIVO 10 mg/mL concentrate for solution for infusion., TIVOZANIB, TIVOZANIB

Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

PL1 - Lyophilisate and solvent for solution for injection, sotatercept

PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection

Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

Placebo for Acetylsalicylic Acid, ACETYLSALICYLIC ACID, REGN7508, Placebo for REGN7508

Placebo for Mitapivat, MITAPIVAT

Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon

Placebo matching < Staccato® alprazolam > and without active substance, alprazolam

Frequently asked questions